Urology & Nephrology News, Treatment Studies | Renal, Urology …
Under a new rule, covered entities are expected to revise HIPAA policies, procedure manuals, and operational workflow to respond to requests for protected health information potentially …
News Archive - Renal and Urology News
Jan 24, 2025 · A systematic review and meta-analysis explored the relationship between androgen deprivation therapy and risk for heart failure in men with prostate cancer who were …
News And Features - Renal and Urology News
Under a new rule, covered entities are expected to revise HIPAA policies, procedure manuals, and operational workflow to respond to requests for protected health information potentially …
Panel Issues New Guidelines for Advanced Prostate Cancer
Jan 13, 2025 · Managing advanced prostate cancer is increasingly complex, with some aspects lacking sufficient level 1 evidence. To address some of the more pressing issues, the 2024 US …
Node-Positive UTUC Management Should Include Radical Surgery
Jan 27, 2025 · Among management options for node-positive upper tract urothelial cancer (UTUC), induction chemotherapy added to radical nephroureterectomy (RNU) provides the …
Only One-Third of Men Receive First-Line mCSPC Treatment ...
Dec 18, 2024 · References: Agarwal N, George DJ, Klaassen Z, et al. Physician reasons for or against treatment intensification in patients with metastatic prostate cancer. JAMA Netw Open. …
Prostate Cancer Overtreatment Persists in Active Surveillance Era
Nov 11, 2024 · References: Daskivich TJ, Luu M, Heard J, Thomas IC, Leppert JT, et al. Overtreatment of prostate cancer among men with limited longevity in the active surveillance era.
Empagliflozin Carryover Effect Found in Patients With Chronic …
Oct 25, 2024 · Empagliflozin continues to provide cardiorenal benefit in patients with chronic kidney disease (CKD) for up to 12 months after it is discontinued, William G. Herrington, …
Finerenone Added to SGLT2i + GLP1-RA Further Reduces …
Oct 30, 2024 · Finerenone further reduces albuminuria in patients with type 2 diabetes and chronic kidney disease (CKD) concurrently taking a sodium-glucose co-transporter 2 inhibitor …
Lumasiran Shows Long-Term Efficacy in Primary Hyperoxaluria …
Oct 29, 2024 · Final results from the phase 3 ILLUMINATE-A trial confirm the clinical benefit of long-term lumasiran treatment in patients with primary hyperoxaluria type 1 (PH1), according …